Bing Yu

机构：Wenzhou Medical University, First Affiliated Hospital of Wenzhou Medical University

发表论文 31 篇 · 总被引 331 次 · h-index 8

代表论文

• Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer (2018 · Journal of Medicinal Chemistry · 被引 128)
• Nucleus accumbens D1/D2 circuits control opioid withdrawal symptoms in mice (2023 · Journal of Clinical Investigation · 被引 48)
• Evaluative performance of TyG-ABSI versus traditional indices in relation to cardiovascular disease and mortality: evidence from the U.S. NHANES (2025 · Cardiovascular Diabetology · 被引 38)
• Role of succinylation modification in central nervous system diseases (2024 · Ageing Research Reviews · 被引 27)
• Correlation between the triglyceride-glucose index and the onset of atrial fibrillation in patients with non-alcoholic fatty liver disease (2023 · Diabetology & Metabolic Syndrome · 被引 21)
• Mrc1 + macrophage-derived IGF1 mitigates crystal nephropathy by promoting renal tubule cell proliferation via the AKT/Rb signaling pathway (2024 · Theranostics · 被引 16)